NEW YORK, Sept. 23 (GenomeWeb News) - ParAllele BioScience said that it has raised $22.5 million in a round of Series B financing.

The round was led by a new investor, Mohr, Davidow Ventures, and included such existing investors as Abingworth Management, Index Ventures, and Versant Ventures.

Proceeds of the financing, said ParAllele, will be used to support the ongoing development and roll out of the company's SNP products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.